{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:52:13Z","timestamp":1792291933966,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41582-024-01025-y","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:02:59Z","timestamp":1728403379000},"page":"685-690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Coeliac disease as a model for understanding multiple sclerosis"],"prefix":"10.1038","volume":"20","author":[{"given":"Natalia","family":"Drosu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2892-6986","authenticated-orcid":false,"given":"Kjetil","family":"Bjornevik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8860-704X","authenticated-orcid":false,"given":"Ludvig M.","family":"Sollid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"1025_CR1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrg3502","volume":"14","author":"M Parkes","year":"2013","unstructured":"Parkes, M., Cortes, A., van Heel, D. A. & Brown, M. A. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat. Rev. Genet. 14, 661\u2013673 (2013).","journal-title":"Nat. Rev. Genet."},{"key":"1025_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature13835","volume":"518","author":"KK Farh","year":"2015","unstructured":"Farh, K. K. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337\u2013343 (2015).","journal-title":"Nature"},{"key":"1025_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375, 296\u2013301 (2022).","journal-title":"Science"},{"key":"1025_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathmechdis-031521-032634","volume":"18","author":"R Iversen","year":"2023","unstructured":"Iversen, R. & Sollid, L. M. The immunobiology and pathogenesis of celiac disease. Annu. Rev. Pathol. 18, 47\u201370 (2023).","journal-title":"Annu. Rev. Pathol."},{"key":"1025_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00251-019-01141-w","volume":"72","author":"LM Sollid","year":"2020","unstructured":"Sollid, L. M. et al. Update 2020: nomenclature and listing of celiac disease-relevant gluten epitopes recognized by CD4+ T cells. Immunogenetics 72, 85\u201388 (2020).","journal-title":"Immunogenetics"},{"key":"1025_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nm0698-713","volume":"4","author":"\u00d8 Molberg","year":"1998","unstructured":"Molberg, \u00d8. et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4, 713\u2013717 (1998).","journal-title":"Nat. Med."},{"key":"1025_CR7","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.4049\/jimmunol.161.4.1585","volume":"161","author":"Y van de Wal","year":"1998","unstructured":"van de Wal, Y. et al. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J. Immunol. 161, 1585\u20131588 (1998).","journal-title":"J. Immunol."},{"key":"1025_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nm0797-797","volume":"3","author":"W Dieterich","year":"1997","unstructured":"Dieterich, W. et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 3, 797\u2013801 (1997).","journal-title":"Nat. Med."},{"key":"1025_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/MPG.0000000000002497","volume":"70","author":"S Husby","year":"2020","unstructured":"Husby, S. et al. European society paediatric gastroenterology, hepatology and nutrition guidelines for diagnosing coeliac disease 2020. J. Pediatr. Gastroenterol. Nutr. 70, 141\u2013156 (2020).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"1025_CR10","first-page":"160","volume":"19","author":"K Bjornevik","year":"2023","unstructured":"Bjornevik, K., Munz, C., Cohen, J. I. & Ascherio, A. Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat. Rev. Neurol. 19, 160\u2013171 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"1025_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","volume":"21","author":"SS Soldan","year":"2023","unstructured":"Soldan, S. S. & Lieberman, P. M. Epstein-Barr virus and multiple sclerosis. Nat. Rev. Microbiol. 21, 51\u201364 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1025_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nri3407","volume":"13","author":"LM Sollid","year":"2013","unstructured":"Sollid, L. M. & Jabri, B. Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat. Rev. Immunol. 13, 294\u2013302 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"1025_CR13","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.tig.2021.04.012","volume":"37","author":"R Martin","year":"2021","unstructured":"Martin, R., Sospedra, M., Eiermann, T. & Olsson, T. Multiple sclerosis: doubling down on MHC. Trends Genet. 37, 784\u2013797 (2021).","journal-title":"Trends Genet."},{"key":"1025_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/gutjnl-2023-331595","volume":"73","author":"MF du Pre","year":"2024","unstructured":"du Pre, M. F., Iversen, R. & Sollid, L. M. Coeliac disease: the paradox of diagnosing a food hypersensitivity disorder with autoantibodies. Gut 73, 844\u2013853 (2024).","journal-title":"Gut"},{"key":"1025_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coi.2014.08.005","volume":"31","author":"LM Sollid","year":"2014","unstructured":"Sollid, L. M., Pos, W. & Wucherpfennig, K. W. Molecular mechanisms for contribution of MHC molecules to autoimmune diseases. Curr. Opin. Immunol. 31, 24\u201330 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"1025_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1025_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","volume":"21","author":"A Svenningsson","year":"2022","unstructured":"Svenningsson, A. et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 21, 693\u2013703 (2022).","journal-title":"Lancet Neurol."},{"key":"1025_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kramer","year":"2023","unstructured":"Kramer, J., Bar-Or, A., Turner, T. J. & Wiendl, H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat. Rev. Neurol. 19, 289\u2013304 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"1025_CR19","doi-asserted-by":"publisher","first-page":"e00747-17","DOI":"10.1128\/JVI.00747-17","volume":"91","author":"JG Kosowicz","year":"2017","unstructured":"Kosowicz, J. G. et al. Drug modulators of B cell signaling pathways and Epstein-Barr virus lytic activation. J. Virol. 91, e00747-17 (2017).","journal-title":"J. Virol."},{"key":"1025_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","volume":"9","author":"RG Caldwell","year":"1998","unstructured":"Caldwell, R. G., Wilson, J. B., Anderson, S. J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405\u2013411 (1998).","journal-title":"Immunity"},{"key":"1025_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2309439","volume":"390","author":"P Vermersch","year":"2024","unstructured":"Vermersch, P. et al. Inhibition of CD40L with frexalimab in multiple sclerosis. N. Engl. J. Med. 390, 589\u2013600 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1025_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1615\/CritRevImmunol.v37.i2-6.100","volume":"37","author":"JD Laman","year":"2017","unstructured":"Laman, J. D., Claassen, E. & Noelle, R. J. Functions of CD40 and its ligand, gp39 (CD40L). Crit. Rev. Immunol. 37, 371\u2013420 (2017).","journal-title":"Crit. Rev. Immunol."},{"key":"1025_CR23","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/emboj\/17.6.1700","volume":"17","author":"E Kilger","year":"1998","unstructured":"Kilger, E., Kieser, A., Baumann, M. & Hammerschmidt, W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 17, 1700\u20131709 (1998).","journal-title":"EMBO J."},{"key":"1025_CR24","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.ade6949","volume":"385","author":"JD Laman","year":"2024","unstructured":"Laman, J. D., Molloy, M. & Noelle, R. J. Switching off autoimmunity. Science 385, 827\u2013829 (2024).","journal-title":"Science"},{"key":"1025_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae110","author":"J Huang","year":"2024","unstructured":"Huang, J. et al. Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis. Brain https:\/\/doi.org\/10.1093\/brain\/awae110 (2024).","journal-title":"Brain"},{"key":"1025_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/gene.2011.42","volume":"13","author":"E Sundqvist","year":"2012","unstructured":"Sundqvist, E. et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun. 13, 14\u201320 (2012).","journal-title":"Genes Immun."},{"key":"1025_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jneuroim.2016.08.016","volume":"299","author":"MM Dooley","year":"2016","unstructured":"Dooley, M. M., de Gannes, S. L., Fu, K. A. & Lindsey, J. W. The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins. J. Neuroimmunol. 299, 147\u2013151 (2016).","journal-title":"J. Neuroimmunol."},{"key":"1025_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1001\/jamaneurol.2024.0272","volume":"81","author":"M Cortese","year":"2024","unstructured":"Cortese, M. et al. Serologic response to the Epstein-Barr virus peptidome and the risk for multiple sclerosis. JAMA Neurol. 81, 515\u2013524 (2024).","journal-title":"JAMA Neurol."},{"key":"1025_CR29","doi-asserted-by":"publisher","first-page":"16955","DOI":"10.1073\/pnas.1902623116","volume":"116","author":"K Tengvall","year":"2019","unstructured":"Tengvall, K. et al. Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc. Natl Acad. Sci. USA 116, 16955\u201316960 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1025_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","volume":"603","author":"TV Lanz","year":"2022","unstructured":"Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and glialCAM. Nature 603, 321\u2013327 (2022).","journal-title":"Nature"},{"key":"1025_CR31","doi-asserted-by":"publisher","first-page":"eadg3032","DOI":"10.1126\/sciadv.adg3032","volume":"9","author":"OG Thomas","year":"2023","unstructured":"Thomas, O. G. et al. Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis. Sci. Adv. 9, eadg3032 (2023).","journal-title":"Sci. Adv."},{"key":"1025_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25927","volume":"89","author":"G Comi","year":"2021","unstructured":"Comi, G. et al. Role of B cells in multiple sclerosis and related disorders. Ann. Neurol. 89, 13\u201323 (2021).","journal-title":"Ann. Neurol."},{"key":"1025_CR33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220650","volume":"219","author":"T Schneider-Hohendorf","year":"2022","unstructured":"Schneider-Hohendorf, T. et al. Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis. J. Exp. Med. 219, e20220650 (2022).","journal-title":"J. Exp. Med."},{"key":"1025_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S1074-7613(00)80493-8","volume":"5","author":"G Khan","year":"1996","unstructured":"Khan, G., Miyashita, E. M., Yang, B., Babcock, G. J. & Thorley-Lawson, D. A. Is EBV persistence in vivo a model for B cell homeostasis? Immunity 5, 173\u2013179 (1996).","journal-title":"Immunity"},{"key":"1025_CR35","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1084\/jem.20071030","volume":"204","author":"B Serafini","year":"2007","unstructured":"Serafini, B. et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204, 2899\u20132912 (2007).","journal-title":"J. Exp. Med."},{"key":"1025_CR36","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/brain\/awp200","volume":"132","author":"SN Willis","year":"2009","unstructured":"Willis, S. N. et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 132, 3318\u20133328 (2009).","journal-title":"Brain"},{"key":"1025_CR37","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1212\/WNL.0b013e3181dabfb5","volume":"74","author":"A Ascherio","year":"2010","unstructured":"Ascherio, A. & Bar-Or, A. EBV and brain matter(s)? Neurology 74, 1092\u20131095 (2010).","journal-title":"Neurology"},{"key":"1025_CR38","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1177\/2050640619874183","volume":"7","author":"S Zuhlke","year":"2019","unstructured":"Zuhlke, S. et al. CD38 expression on gluten-specific T cells is a robust marker of gluten re-exposure in coeliac disease. United European Gastroenterol. J. 7, 1337\u20131344 (2019).","journal-title":"United European Gastroenterol. J."},{"key":"1025_CR39","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1212\/WNL.37.7.1097","volume":"37","author":"HS Panitch","year":"1987","unstructured":"Panitch, H. S., Hirsch, R. L., Schindler, J. & Johnson, K. P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37, 1097\u20131102 (1987).","journal-title":"Neurology"},{"key":"1025_CR40","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.4049\/jimmunol.1601693","volume":"198","author":"B Jabri","year":"2017","unstructured":"Jabri, B. & Sollid, L. M. T cells in celiac disease. J. Immunol. 198, 3005\u20133014 (2017).","journal-title":"J. Immunol."},{"key":"1025_CR41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1084\/jem.20060028","volume":"203","author":"B Meresse","year":"2006","unstructured":"Meresse, B. et al. Reprogramming of CTLs into natural killer-like cells in celiac disease. J. Exp. Med. 203, 1343\u20131355 (2006).","journal-title":"J. Exp. Med."},{"key":"1025_CR42","doi-asserted-by":"publisher","first-page":"eadf4312","DOI":"10.1126\/sciimmunol.adf4312","volume":"8","author":"A Kornberg","year":"2023","unstructured":"Kornberg, A. et al. Gluten induces rapid reprogramming of natural memory \u03b1\u03b2 and \u03b3\u03b4 intraepithelial T cells to induce cytotoxicity in celiac disease. Sci. Immunol. 8, eadf4312 (2023).","journal-title":"Sci. Immunol."},{"key":"1025_CR43","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/eji.202048974","volume":"51","author":"LM Eggesbo","year":"2021","unstructured":"Eggesbo, L. M. et al. Single-cell TCR repertoire analysis reveals highly polyclonal composition of human intraepithelial CD8+ \u03b1\u03b2 T lymphocytes in untreated celiac disease. Eur. J. Immunol. 51, 1542\u20131545 (2021).","journal-title":"Eur. J. Immunol."},{"key":"1025_CR44","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.immuni.2004.06.020","volume":"21","author":"B Meresse","year":"2004","unstructured":"Meresse, B. et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21, 357\u2013366 (2004).","journal-title":"Immunity"},{"key":"1025_CR45","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.immuni.2004.06.018","volume":"21","author":"S Hue","year":"2004","unstructured":"Hue, S. et al. A direct role for NKG2D\/MICA interaction in villous atrophy during celiac disease. Immunity 21, 367\u2013377 (2004).","journal-title":"Immunity"},{"key":"1025_CR46","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1523\/JNEUROSCI.4402-06.2007","volume":"27","author":"P Saikali","year":"2007","unstructured":"Saikali, P. et al. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J. Neurosci. 27, 1220\u20131228 (2007).","journal-title":"J. Neurosci."},{"key":"1025_CR47","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200149","volume":"10","author":"MCG Monaco","year":"2023","unstructured":"Monaco, M. C. G. et al. EBNA1 inhibitors block proliferation of spontaneous lymphoblastoid cell lines from patients with multiple sclerosis and healthy controls. Neurol. Neuroimmunol. Neuroinflamm. 10, e200149 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1025_CR48","doi-asserted-by":"publisher","first-page":"12368","DOI":"10.1073\/pnas.2002392117","volume":"117","author":"NC Drosu","year":"2020","unstructured":"Drosu, N. C., Edelman, E. R. & Housman, D. E. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase. Proc. Natl Acad. Sci. USA 117, 12368\u201312374 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1025_CR49","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.4049\/jimmunol.1301629","volume":"191","author":"RJ Abbott","year":"2013","unstructured":"Abbott, R. J. et al. CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response. J. Immunol. 191, 5398\u20135409 (2013).","journal-title":"J. Immunol."},{"key":"1025_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000583","volume":"2","author":"D Adhikary","year":"2007","unstructured":"Adhikary, D. et al. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS One 2, e583 (2007).","journal-title":"PLoS One"},{"key":"1025_CR51","doi-asserted-by":"publisher","first-page":"105444","DOI":"10.1016\/j.msard.2024.105444","volume":"82","author":"N Drosu","year":"2024","unstructured":"Drosu, N. et al. In the era of antiviral trials for MS, the answer lies in the details. Mult. Scler. Relat. Disord. 82, 105444 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1025_CR52","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41564-024-01699-6","volume":"9","author":"SS Soldan","year":"2024","unstructured":"Soldan, S. S. et al. Multiple sclerosis patient-derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease. Nat. Microbiol. 9, 1540\u20131554 (2024).","journal-title":"Nat. Microbiol."},{"key":"1025_CR53","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1086\/589714","volume":"198","author":"SE Hoover","year":"2008","unstructured":"Hoover, S. E., Kawada, J., Wilson, W. & Cohen, J. I. Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells. J. Infect. Dis. 198, 318\u2013323 (2008).","journal-title":"J. Infect. Dis."},{"key":"1025_CR54","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41591-019-0403-9","volume":"25","author":"A Christophersen","year":"2019","unstructured":"Christophersen, A. et al. Distinct phenotype of CD4+ T cells driving celiac disease identified in multiple autoimmune conditions. Nat. Med. 25, 734\u2013737 (2019).","journal-title":"Nat. Med."},{"key":"1025_CR55","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.gastro.2024.03.027","volume":"167","author":"LF Risnes","year":"2024","unstructured":"Risnes, L. F. et al. Gluten-free diet induces rapid changes in phenotype and survival properties of gluten-specific T cells in celiac disease. Gastroenterology 167, 250\u2013263 (2024).","journal-title":"Gastroenterology"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01025-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01025-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01025-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T14:05:00Z","timestamp":1730210700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01025-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1038\/s41582-024-01025-y","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"11 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.B. and M.C. have received funding from the European Commission under the Horizon Europe funding programme to conduct a clinical trial of tenofovir alafenamide for the treatment of multiple sclerosis (project number 101136991; ). All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}